CING Profile
Cingulate Inc., a clinical-stage biopharmaceutical firm, specializes in advancing treatments for attention-deficit/hyperactivity disorder (ADHD). The company's primary focus is on developing innovative product candidates aimed at addressing the therapeutic needs within the ADHD space. Leading its pipeline are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both currently progressing through phase 3 clinical trials. These candidates hold promise for enhancing treatment options for ADHD patients.
In addition to its ADHD portfolio, Cingulate Inc. is actively developing CTx-2103, targeting the treatment of anxiety disorders. This diversified approach underscores the company's commitment to addressing significant neurological and psychiatric conditions through novel therapeutic advancements.
Founded in 2012 and headquartered in Kansas City, Kansas, Cingulate Inc. has steadily advanced its clinical programs while maintaining a focus on rigorous research and development. The company's location in Kansas City strategically positions it within a thriving biopharmaceutical ecosystem, facilitating collaborations and leveraging local resources to support its innovative pipeline.
As Cingulate Inc. continues to progres its product candiidates through clinical trials, it remains dedicated to improving patient outcomes in ADHD and anxiety disorders. The company's efforts in drug development reflect its mission to bring impactful therapies to market, addressing critical unmet medical needs in mental health care.
|
